New Funding Boosts Infectious Disease Research Projects
Public and private organizations commit €159 million to accelerate clinical trials for diseases like malaria and tuberculosis.
Updated on Oct. 15, 2026 in COVID-19
Live Poll
Do you believe public-private partnerships effectively solve major global health challenges?
Public and private organizations have pledged €159 million to the Global Health EDCTP3 to support infectious disease research. This collaborative initiative connects roughly 100 organizations to fund and develop health projects across Africa and Europe.
Why it matters
Pooling resources through these partnerships provides the critical mass necessary for late-stage clinical trials. This collaborative model aims to ensure research stays relevant while strengthening clinical infrastructure in African institutions.
The funding follows an official report of research commitments totaling €159 million to support collaborative projects. While call-level contributions are expected to exceed €49 million by the end of 2026, the long-term impact on specific disease eradication remains under investigation.
The players
Global Health EDCTP3
A joint undertaking that manages public-private partnerships to advance infectious disease research in Africa and Europe.
Gates Foundation
A major philanthropic organization focused on global health equity, infectious disease control, and vaccine development.
BioNTech
A biotechnology company known for developing mRNA-based therapies and vaccines for infectious diseases and oncology.
Novartis
A global pharmaceutical company that researches and develops therapies for a wide range of diseases including malaria.
International AIDS Vaccine Initiative
A non-profit scientific research organization working to develop accessible, globally relevant vaccines and treatments.
The details
The program functions by integrating product-development expertise with research partnerships, allowing public and private entities to co-create calls for proposals. This structure supports advanced clinical efforts, such as the WANECAM 3 project, which is developing a single-dose malaria cure, and IAVI-led clinical trials testing the MTBVAC tuberculosis vaccine in sub-Saharan Africa. By combining funding with technical guidance, the initiative seeks to overcome resource barriers that often stall large-scale infectious disease trials.
Timeline
End of 2026: Call-level contributions will exceed €49 million.
December 2026: The 2027 Work Programme will be published.
January 2027: A networking platform for partners will launch.
5-9 April 2027: The 13th edition of the EDCTP Forum will take place in Madrid.
Health Landscape
This influx of funding marks a significant expansion of the Global Health EDCTP3 Work Programme's capacity to facilitate cross-border clinical trials. It represents a shift toward more robust, multi-sector integration to solve persistent health challenges in developing regions.
These projects primarily support the development of new treatments for malaria and tuberculosis, which may impact future global health standards. Readers interested in the progress of these specific vaccine and drug trials should follow future updates on clinical trial registration sites.
The takeaway
Large-scale collaboration is essential for moving infectious disease research into late-stage clinical testing. If you are interested in medical advancements, monitor major research forums like the upcoming EDCTP event for updates on clinical trial progress.
Further reading
For broader trends in international disease research and pandemic preparedness, see our COVID-19 section.
More information
Review the full List of global health co-investors for additional project details.
Source note: This article includes information reported by Science Business.
Live Poll
Do you believe public-private partnerships effectively solve major global health challenges?
